Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.
van Ojik HH, Repp R, Groenewegen G, Valerius T, van de Winkel JG. van Ojik HH, et al. Among authors: van de winkel jg. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):207-9. doi: 10.1007/s002620050434. Cancer Immunol Immunother. 1997. PMID: 9435875 Free PMC article. Clinical Trial. No abstract available.
Immunotherapeutic perspective for bispecific antibodies.
van Spriel AB, van Ojik HH, van De Winkel JG. van Spriel AB, et al. Among authors: van ojik hh, van de winkel jg. Immunol Today. 2000 Aug;21(8):391-7. doi: 10.1016/s0167-5699(00)01659-5. Immunol Today. 2000. PMID: 10916142 Review.
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo YM, Blijham GH, Kalden JR, van de Winkel JG, Gramatzki M. Repp R, et al. Among authors: van ojik hh. Br J Cancer. 2003 Dec 15;89(12):2234-43. doi: 10.1038/sj.bjc.6601367. Br J Cancer. 2003. PMID: 14676800 Free PMC article. Clinical Trial.
Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
Heijnen IA, Rijks LJ, Schiel A, Stockmeyer B, van Ojik HH, Dechant M, Valerius T, Keler T, Tutt AL, Glennie MJ, van Royen EA, Capel PJ, van de Winkel JG. Heijnen IA, et al. Among authors: van royen ea, van ojik hh, van de winkel jg. J Immunol. 1997 Dec 1;159(11):5629-39. J Immunol. 1997. PMID: 9548506
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection.
Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, van Lent PL, Hofhuis FM, van Ojik HH, Sedlik C, da Silveira SA, Gerber J, de Jong YF, Roozendaal R, Aarden LA, van den Berg WB, Saito T, Mosser D, Amigorena S, Izui S, van Ommen GJ, van Vugt M, van de Winkel JG, Verbeek JS. Ioan-Facsinay A, et al. Among authors: van vugt m, van lent pl, van ommen gj, van ojik hh, van den berg wb, van de winkel jg. Immunity. 2002 Mar;16(3):391-402. doi: 10.1016/s1074-7613(02)00294-7. Immunity. 2002. PMID: 11911824 Free article.
IL-12: a promising adjuvant for cancer vaccination.
Portielje JE, Gratama JW, van Ojik HH, Stoter G, Kruit WH. Portielje JE, et al. Among authors: van ojik hh. Cancer Immunol Immunother. 2003 Mar;52(3):133-44. doi: 10.1007/s00262-002-0356-5. Epub 2003 Feb 12. Cancer Immunol Immunother. 2003. PMID: 12649742 Free PMC article. Review.
16 results